Shares of Innoviva Inc. (INVA), a diversified holding company with a portfolio of royalties and other healthcare assets, have lost nearly 14% of their value year-to-date to trade around $11.
The company's royalty portfolio is made up of respiratory assets partnered with Glaxo Group Limited including RELVAR/BREO ELLIPTA and ANORO ELLIPTA.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.